Naphazoline + pheniramine


Full Prescribing Info
Dosage/Direction for Use

Ophthalmic
Ocular allergy
Adult: As combination containing naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%: Apply 1-2 drops in the affected eye up to 4 times daily.
Contraindications
Angle closure glaucoma.
Special Precautions
Glaucoma, hypertension, CV abnormalities, DM, hyperthyroidism, infection, or injury. Pregnancy and lactation. Avoid in infants and young children <6 yr. Rebound congestion may occur with prolonged use or overuse. Patient to seek medical advice if there is ocular pain, vision changes, worsening of redness or irritation of the eye or symptoms lasts >72 hr. Remove contact lens before use.
Adverse Reactions
Blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. When used in high doses in elderly, naphazoline may liberate pigment granules from the iris.
Drug Interactions
Increased pressor effects with maprotiline or TCA. Possibility of severe hypertensive reaction with MAOI.
Action
Naphazoline, an imidazoline derivative is a sympathomimetic with α-adrenergic activity. It produces vasoconstriction. When applied topically to mucous membranes, it reduces swelling and congestion. It is often used in combination with pheniramine, an alkylamine derivative antihistamine, in ophthalmic preparations.
Onset: Local vasoconstriction: Within 10 minutes
Duration: Local vasoconstriction: 2-6 hr
ATC Classification
S01GA01 - naphazoline ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
R01AB02 - naphazoline ; Belongs to the class of topical sympathomimetic combination preparations, excluding corticosteroids. Used as nasal decongestants.
R01AA08 - naphazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
D04AA16 - pheniramine ; Belongs to the class of topical antihistamines used in the treatment of pruritus.
R06AB05 - pheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
Disclaimer: This information is independently developed by CIMS based on naphazoline + pheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in